Due to the use of dual human epidermal growth factor receptor 2 (HER2) blockade and platinum-based neoadjuvant chemotherapy, the rate of pCR rate in HER2 positive (HER2+) or triple-negative breast cancer (TNBC) patients has increased to more than 30% (5). Here, ERBB2 is linked to triple-negative breast carcinoma.